Key result
A 50-year-old male with Hodgkin's disease developed fatal massive liver necrosis during the fourth cycle of ABVD chemotherapy, potentially caused by dacarbazine.
Why the study?
Does ABVD chemotherapy cause fatal liver necrosis in patients with Hodgkin's disease?
Case Report (n=1)
Does ABVD chemotherapy cause fatal liver necrosis in patients with Hodgkin's disease?
ABVD chemotherapy, potentially due to dacarbazine, can cause fatal liver necrosis, highlighting the need to monitor for unexplained hepatomegaly and elevated liver enzymes during treatment.
May signal dacarbazine hepatotoxicity in ABVD; leaves open causality and monitoring needs in Hodgkin lymphoma.
A case of massive fatal liver necrosis during chemotherapy for stage IVA Hodgkin's disease is described. A previously healthy 50-year-old male was given doxorubicin 25 mg/m2, bleomycin 10 mg/m2 and vinblastine 6 mg/m2 on days 1 and 14 of the cycle combined with dacarbazine 150 mg/m2 on days 1-5 (ABVD) with 4-week intervals. During the fourth cycle of chemotherapy the patient developed fatal liver necrosis with anuria and uncontrolled bleeding. At autopsy, 80% of the liver was necrotic and viable cells were seen only in periportal areas. Dacarbazine may have caused the necrosis. Liver necrosis caused by drugs should be considered if unexplained hepatomegaly and a rise in serum liver enzyme levels is noted during ABVD treatment.
No takes yet. Share an insight, caveat, or question.
Joensuu et al. (1986) conducted a case report in Stage IVA Hodgkin's disease (n=1). ABVD chemotherapy was evaluated on Fatal liver necrosis. A 50-year-old male with Hodgkin's disease developed fatal massive liver necrosis during the fourth cycle of ABVD chemotherapy, potentially caused by dacarbazine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: